Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model

doi:10.1016/0024-3205(89)90272-5

Life Sciences

Volume 45, Issue 18, 1989, Pages 1627-1636

https://doi.org/10.1016/0024-3205(89)90272-5 Get rights and content

Abstract

To determine whether the differences in development of acute tolerance to several morphine actions correlate with the mu receptor subtype mediating them, we have examined the appearance of acute tolerance to analgesia, respiratory depression, gastrointestinal transit, and hormone release in an intravenous morphine infusion model. Analgesia, a naloxonazine-sensitive mu₁ action, peaked at 2 hr after initiation of the infusions. The log dose-response relationship of the infusion rate to peak tailflick latency was linear from 10 to 50 μg/kg/min. By 8 hr, the tailflick latencies declined nearly to baseline levels, implying the rapid development of tolerance. Tolerance to morphine-induced prolactin release, another mu₁ action, also developed rapidly over 8 hr. In contrast, two mu₂ actions, respiratory depression measured with arterial blood gas determinations and gastrointestinal transit, showed no significant tolerance over a similar 8 hr infusion. We also observed no tolerance to morphine-induced growth hormone release, a non-mu₁ action, over the same period. Thus, these results demonstrate that mu₁ actions develop tolerance in an infusion model far more rapidly than a number of naloxonazine-insensitive (non-mu₁) ones and may help explain differences in the rate of tolerance development to morphine actions.

References (51)

S.C. Roerig et al.
Brain Res.
(1987)
W.R. Martin et al.
J. Psychiat Res.
(1969)
M. Wuster et al.
Biochem Pharmacol.
(1981)
G.W. Pasternak et al.
Life Sci.
(1986)
P.L. Wood et al.
Life Sci.
(1982)
R.A. Lutz et al.
Biochem. Biophys. Res. Comm.
(1984)
L. Toll et al.
Neuropeptides
(1984)
R.B. Rothman et al.
Peptides
(1987)
D. Paul et al.
Eur. J. Pharmacol.
(1988)
D.I. Macht et al.
J. Am. Pharm. Assoc. Sci. Ed.
(1931)

W.R. Martin et al.

J. Pharmacol. Exp. Ther.

(1961)

E.L. Way et al.

J. Pharmacol. Exp. Ther.

(1969)

L. Shuster

J.H. Jaffe et al.

A.P. Smith et al.

H.O.J. Collier

Nature

(1965)

J. Cochin

Fed. Proc.

(1970)

M.H. Seevers et al.

Am. J. Med.

(1954)

J. Cochin et al.

J. Pharm. Exp. Ther.

(1964)

A. Goldstein et al.

W.R. Martin et al.

J. Pharmacol. Exp. Therap.

(1976)

J.A.H. Lord et al.

Nature

(1977)

B.L. Wolozin et al.

Proc. Nat. Acad. Sci. USA

(1981)

R. Schulz et al.

Mol. Pharmacol.

(1980)

R. Schulz et al.

J. Pharmacol. Exp. Ther.

(1981)

Cited by (125)

Which Opioids Are Safest and Most Effective in Patients With Renal or Hepatic Failure?
2023, Evidence-Based Practice of Palliative Medicine, Second Edition
When selecting an analgesic for a specific patient, both patient- and drug-related variables must be considered. This chapter discusses the pharmacodynamic and pharmacokinetic changes associated with opioid therapy in the face of renal and/or hepatic impairment and offers guidance for dosage reduction as appropriate. Understanding how renal and/or hepatic disease impacts the metabolism and/or elimination of opioids will help practitioners select the safest opioid for a patient.
Opioid-induced bowel disorder and narcotic bowel syndrome
2023, Handbook of Gastrointestinal Motility and Disorders of Gut-Brain Interactions, Second Edition
The use of opioids has increased significantly since the 1990s, and along with it, the increase of opioid associated side effects. The two major gastrointestinal side effects of opioids use are opioid-induced bowel disorders (OIBD) and narcotic bowel syndrome (NBS). The most common OIBD is opioid-induced constipation (OIC). OIC has a negative effect on quality of life and is associated with a significant economic impact. NBS or opioid-induced hyperalgesia is characterized by the paradoxical increase in the severity of chronic abdominal pain despite the use of continuous or increasing doses of opioids prescribed for abdominal pain. These patients will have improvement of their abdominal pain when opioids are withdrawn. OIBD and NBS are under-recognized due to lack of awareness, and because these conditions may coexist with functional bowel disorders. We describe the pathophysiology and management of these disorders. Several different pharmaceutical approaches have been developed to prevent and treat OIC. Evidence-based guidelines have been developed for management of OIC.
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology
2022, Pharmacology and Therapeutics
Morphine and other mu-opioid receptor (MOR) agonists remain the mainstay treatment of acute and prolonged pain states worldwide. The major limiting factor for continued use of these current opioids is the high incidence of side effects that result in loss of life and loss of quality of life. The development of novel opioids bereft, or much less potent, at inducing these side effects remains an intensive area of research, with multiple pharmacological strategies being explored. However, as with many G protein-coupled receptors (GPCRs), translation of promising candidates from in vitro characterisation to successful clinical candidates still represents a major challenge and attrition point. This review summarises the preclinical animal models used to evaluate the key opioid-induced behaviours of antinociception, respiratory depression, constipation and opioid-induced hyperalgesia and tolerance. We highlight the influence of distinct variables in the experimental protocols, as well as the potential implications for differences in receptor reserve in each system. Finally, we discuss how methods to assess opioid action in vivo and in vitro relate to each other in the context of bridging the translational gap in opioid drug discovery.
Opioid-induced bowel disorder and narcotic bowel syndrome
2019, Clinical and Basic Neurogastroenterology and Motility
The use of opioids in the past 25 years has increased significantly, and along with it, the increase of opioid associated side effects. The two major gastrointestinal side effects of opioids use are opioid-induced bowel disorders (OIBD) and narcotic bowel syndrome (NBS). The most common OIBD is opioid-induced constipation (OIC). OIC has a negative effect on quality of life and is associated with a significant economic impact. NBS or opioid-induced hyperalgesia is characterized by the paradoxical increase in the severity of chronic abdominal pain despite the use of continuous or increasing doses of opioids prescribed for abdominal pain. These patients will have improvement of their abdominal pain when opioids are withdrawn. OIBD and NBS are under-recognized due to lack of awareness, especially because these conditions may co-exist with functional bowel disorders. We describe the pathophysiology and management of these disorders. Several different pharmaceutical approaches have been developed to prevent and treat OIC. Evidence-based guidelines have been developed for management of OIC.
Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits
2017, Clinical Gastroenterology and Hepatology
The use of opioid medications on both an acute and chronic basis is ubiquitous in the United States. As opioid receptors densely populate the gastrointestinal tract, symptoms and side effects can be expected in these patients. In the esophagus, dysmotility may result, manifesting with dysphagia and a syndrome indistinguishable from primary achalasia. In the stomach, a marked delay in gastric emptying may occur with postprandial nausea and early satiety. Postoperatively, particularly with abdominal surgery, opioid-induced ileus may ensue. In the colon, opioid-induced constipation is common. A unique syndrome termed narcotic bowel syndrome is characterized by chronic abdominal pain often accompanied by nausea and vomiting in the absence of other identifiable causes. With the recognition of the important role of opioids on gastrointestinal function, novel drugs have been developed that use this physiology. These medications include peripheral acting opioid agonists to treat opioid-induced constipation and combination agonist and antagonists used for diarrhea-predominant irritable bowel syndrome. This review summarizes the most recent data in these areas.
Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone
2017, International Journal of Drug Policy
Citation Excerpt :
The occurrence of opioid poisoning has been associated with changes in tolerance. Tolerance to opioids develops quickly, with evidence of tolerance to morphine exhibited as early as 8 h during continuous intravenous infusions in rats (Kissin, Brown, Robinson, & Bradley, 1991; Ling, Paul, Simantov, & Pasternak, 1989). Following periods of abstinence, the tolerance built over periods of regular use is reversed and the opioid system up-regulates and re-sensitizes to an approximate pre-opioid use level.
Illicit opioid use is associated with high rates of fatal and non-fatal opioid overdose. This study aims to compare rates of fatal and serious but non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone, and to identify risk factors for fatal opioid overdose.
Opioid dependent patients treated with methadone (n = 3515), buprenorphine (n = 3250) or implant naltrexone (n = 1461) in Western Australia for the first time between 2001 and 2010, were matched against state mortality and hospital data. Rates of fatal and non-fatal serious opioid overdoses were calculated and compared for the three treatments. Risk factors associated with fatal opioid overdose were examined using multivariate cox proportional hazard models.
No significant difference was observed between the three groups in terms of crude rates of fatal or non-fatal opioid overdoses. During the first 28 days of treatment, rates of non-fatal opioid overdose were high in all three groups, as were fatal opioid overdoses in patients treated with methadone. However, no fatal opioid overdoses were observed in buprenorphine or naltrexone patients during this period. Following the first 28 days, buprenorphine was shown to be protective, particularly in terms of non-fatal opioid overdoses. After the cessation of treatment, rates of fatal and non-fatal opioid overdoses were similar between the groups, with the exception of lower rates of non-fatal opioid overdose in the naltrexone treated patients compared with the methadone treated patients. After the commencement of treatment, gender, and hospitalisations with a diagnosis of opioid poisoning, cardiovascular or mental health problems were significant predictors of subsequent fatal opioid overdose.
Rates of fatal and non-fatal opioid overdose were not significantly different in patients treated with methadone, buprenorphine or implant naltrexone. Gender and prior cause-specific hospitalisations can be used to identify patients at a high risk of fatal opioid overdose.

View all citing articles on Scopus

View full text

Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model

Abstract

Brain Res.

J. Psychiat Res.

Biochem Pharmacol.

Life Sci.

Life Sci.

Biochem. Biophys. Res. Comm.

Neuropeptides

Peptides

Eur. J. Pharmacol.

J. Am. Pharm. Assoc. Sci. Ed.

J. Pharmacol. Exp. Ther.

J. Pharmacol. Exp. Ther.

Nature

Fed. Proc.

Am. J. Med.

J. Pharm. Exp. Ther.

J. Pharmacol. Exp. Therap.

Nature

Proc. Nat. Acad. Sci. USA

Mol. Pharmacol.

J. Pharmacol. Exp. Ther.